Etanercept Biosimilar - Research Grade

Barakat, R., Al-Sarraf, H. & Redzic, Z. Hypoxemia exerts detrimental effects on the choroid plexuses and cerebrospinal fluid system in rats. Fluids Barriers CNS, 2025, 22, 27.

Lee, E.J., Song, J., Yoon, S. et al. Matrix-assisted laser desorption/ionization mass spectrometry-based relative quantification of N-glycans in etanercept and its biosimilar using the stable isotope label Girard’s reagent P. Biotechnol Bioproc E, 2026.

Human

TNF alpha

>1mg/ml

Humanized

Anti-Mouse TNF Alpha (TN3-19.12) In Vivo Antibody - Low Endotoxin (ICH1136), Adalimumab Biosimilar - Research Grade (ICH4001), Infliximab Biosimilar - Research Grade (ICH4006), Zigakibart Biosimilar - Research Grade (ICH5291), Certolizumab Biosimilar - Research Grade (ICH5309), Golimumab Biosimilar - Research Grade (ICH5312), Afelimomab Biosimilar - Research Grade (ICH5331), Licaminlimab Biosimilar - Research Grade (ICH5643), Nerelimomab Biosimilar - Research Grade (ICH5708), Onercept Biosimilar - Research Grade (ICH5732), Placulumab Biosimilar - Research Grade (ICH5776)

https://www.imgt.org/mAb-DB/

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P01375

7124

RRID:AB_2921635

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of etanercept supplied strictly for research use. Etanercept is a soluble decoy built by fusing the extracellular ligand-binding portion of the p75 TNF receptor (TNFR2/TNFRSF1B) to the Fc region of human IgG1; it works by capturing soluble TNF alpha (and lymphotoxin-alpha) before they can engage cell-surface TNF receptors. The research-grade analog reproduces this TNF-binding decoy activity, making it a useful tool for interrogating TNF signalling in vitro: as a neutralising reagent to titrate or block TNF alpha in cell assays, as a positive/reference control alongside anti-TNF antibody biosimilars, and in binding, competition, and bioassay development work. Because it is provided unconjugated, at low endotoxin levels (research grade <1 EU/mg; ultra-low <0.5 EU/mg), and in bulk milligram-to-gram quantities, it suits reproducible, scaled preclinical and method-development experiments. It is not the clinical product and is not intended for human or veterinary use. Guidance provided for ichorbio to review. TNF alpha (tumour necrosis factor; gene TNF, UniProt P01375) is a pleiotropic pro-inflammatory cytokine of the TNF superfamily. It is produced chiefly by activated macrophages and monocytes, as well as T cells, NK cells and others, first as a type II transmembrane protein that is cleaved by the metalloprotease TACE/ADAM17 to release the soluble form; both forms assemble into biologically active homotrimers. TNF alpha signals through two receptors: TNFR1 (p55, TNFRSF1A), broadly expressed and able to drive NF-kB-dependent inflammatory gene expression as well as apoptotic and necroptotic cell death, and TNFR2 (p75, TNFRSF1B), more restricted and preferentially engaged by membrane TNF. Downstream pathways include NF-kB and MAPK activation, orchestrating inflammation, immune cell recruitment, and tissue remodelling. Dysregulated TNF alpha is central to rheumatoid arthritis, psoriasis, and inflammatory bowel disease, making it a validated therapeutic and research target.

Tumor necrosis factor

Detects human TNF. This non-therapeutic fusion-protein uses the same sequence as the therapeutic Etanercept.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Etanercept (anti-TNF alpha) Biosimilar

Q: Is the Etanercept biosimilar available in gram quantities?

A: Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Etanercept biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Etanercept biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar analog of Etanercept that binds human TNF alpha; for research use only (RUO).